Global Rapid Diagnostics market will reach $ 77,095.6 million by 2031, growing by 7.4% annually over 2021-2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations.
Highlighted with 83 tables and 97 figures, this 183-page report “Global Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire global Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Region.
Based on Product, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Based on Prescription, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Professional Diagnostics
• OTC Based Testing
By Platform, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
o Lateral Flow Assays
o Serological Assays
o Other Immunoassays
• Molecular Detection
o Polymerase Chain Reaction (PCR)
o Other Molecular Detection Tests
• Other Platforms
By Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
o COVID-19 Testing
o Healthcare-associated Infections (HAI) Testing
o Hepatitis Testing
o Tropical Diseases Testing
o HIV Testing
o Influenza Testing
o Sexually Transmitted Diseases (STD) Testing
o Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications
By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals & Clinics
• Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE，Saudi Arabia， South Africa and Rest of MEA)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of each national market by Product, Prescription and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Becton Dickinson and Co.
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems
F. Hoffmann La Roche Ltd.
Meridian Bioscience Inc.
OraSure Technologies Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trinity Biotech Plc
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)